Chronic Heart Failure - Pipeline Review, H1 2016

  • ID: 3720470
  • Report
  • 157 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Bayer AG
  • Celyad SA
  • Mast Therapeutics, Inc.
  • Mesoblast Limited
  • MORE
Chronic Heart Failure - Pipeline Review, H1 2016

Summary

‘Chronic Heart Failure - Pipeline Review, H1 2016’, provides an overview of the Chronic Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews pipeline therapeutics for Chronic Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Chronic Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Heart Failure

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes MG, Inc.
  • Bayer AG
  • Celyad SA
  • Mast Therapeutics, Inc.
  • Mesoblast Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Chronic Heart Failure Overview

Therapeutics Development

Pipeline Products for Chronic Heart Failure – Overview

Pipeline Products for Chronic Heart Failure – Comparative Analysis

Chronic Heart Failure – Therapeutics under Development by Companies

Chronic Heart Failure – Therapeutics under Investigation by Universities/Institutes

Chronic Heart Failure – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Chronic Heart Failure – Products under Development by Companies

Chronic Heart Failure – Products under Investigation by Universities/Institutes

Chronic Heart Failure – Companies Involved in Therapeutics Development

Amgen Inc.

AnGes MG, Inc.

Bayer AG

Capricor Therapeutics, Inc.

Celyad SA

Juventas Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Les Laboratoires Servier SAS

Mast Therapeutics, Inc.

Mesoblast Limited

Novartis AG

Pfizer Inc.

PhaseBio Pharmaceuticals, Inc.

Sanofi

Stemedica Cell Technologies, Inc.

Vichem Chemie Research Ltd.

Zensun (Shanghai) Sci & Tech Co., Ltd.

Chronic Heart Failure – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(sacubitril + valsartan) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BAY-1067197 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

beperminogene perplasmid - Drug Profile

Product Description

Mechanism of Action

R&D Progress

C3BSCQR-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cenderitide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CLR-325 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

F-373280 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

finerenone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

furosemide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ivabradine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MPC-150IM - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Neucardin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

omecamtiv mecarbil MR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PB-1046 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAR-296968 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

serelaxin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Chronic Heart Failure - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vepoloxamer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vericiguat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Chronic Heart Failure – Recent Pipeline Updates

Chronic Heart Failure - Dormant Projects

Chronic Heart Failure – Discontinued Products

Chronic Heart Failure – Product Development Milestones

Featured News & Press Releases

Apr 04, 2016: Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure

Apr 04, 2016: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo

Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless

Mar 22, 2016: CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center

Mar 18, 2016: Celyad notifies the European Medicines Agency of its intention to file a Marketing Authorization Application for C-Cure

Jan 20, 2016: Breakthrough drug for heart failure now available in the UK

Dec 23, 2015: Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference

Dec 21, 2015: Celyad receives clearance from the US FDA on its CHART-2 Phase III IND

Dec 02, 2015: New heart failure therapy projected to increase life expectancy

Dec 01, 2015: CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chronic Heart Failure, H1 2016

Number of Products under Development for Chronic Heart Failure – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Chronic Heart Failure – Pipeline by Amgen Inc., H1 2016

Chronic Heart Failure – Pipeline by AnGes MG, Inc., H1 2016

Chronic Heart Failure – Pipeline by Bayer AG, H1 2016

Chronic Heart Failure – Pipeline by Capricor Therapeutics, Inc., H1 2016

Chronic Heart Failure – Pipeline by Celyad SA, H1 2016

Chronic Heart Failure – Pipeline by Juventas Therapeutics, Inc., H1 2016

Chronic Heart Failure – Pipeline by Laboratoires Pierre Fabre SA, H1 2016

Chronic Heart Failure – Pipeline by Les Laboratoires Servier SAS, H1 2016

Chronic Heart Failure – Pipeline by Mast Therapeutics, Inc., H1 2016

Chronic Heart Failure – Pipeline by Mesoblast Limited, H1 2016

Chronic Heart Failure – Pipeline by Novartis AG, H1 2016

Chronic Heart Failure – Pipeline by Pfizer Inc., H1 2016

Chronic Heart Failure – Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016

Chronic Heart Failure – Pipeline by Sanofi, H1 2016

Chronic Heart Failure – Pipeline by Stemedica Cell Technologies, Inc., H1 2016

Chronic Heart Failure – Pipeline by Vichem Chemie Research Ltd., H1 2016

Chronic Heart Failure – Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Chronic Heart Failure Therapeutics – Recent Pipeline Updates, H1 2016

Chronic Heart Failure – Dormant Projects, H1 2016

Chronic Heart Failure – Dormant Projects (Contd..1), H1 2016

Chronic Heart Failure – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Chronic Heart Failure, H1 2016

Number of Products under Development for Chronic Heart Failure – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Amgen Inc.
AnGes MG, Inc.
Bayer AG
Capricor Therapeutics, Inc.
Celyad SA
Juventas Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Les Laboratoires Servier SAS
Mast Therapeutics, Inc.
Mesoblast Limited
Novartis AG
Pfizer Inc.
PhaseBio Pharmaceuticals, Inc.
Sanofi
Stemedica Cell Technologies, Inc.
Vichem Chemie Research Ltd.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll